Please login to the form below

Not currently logged in
Email:
Password:

William Humphries joins board of Clearside Biomedical

New CEO of Merz Pharma’s US operations joins the eyecare firm's board

Clearside Biomedical has appointed CEO of Merz Pharma's North American operations, William Humphries, to its board of directors.

Humphries joins the US-based firm, which specialises in developing eyecare products, just two weeks after his appointment at Merz Inc.

Clearside will be keen to make use of Humphries' 25 years' experience in the pharma industry as it looks to develop its microinjection platform to develop therapeutics for sight threatening conditions such as macular oedema and vascular leakage.

Prior to his appointment at Merz, Humphries was president of the GlaxoSmithKline company Stiefel, which specialises in dermatology.

Humphries has also held senior executive roles at Allergan, including VP of its US skincare business.

"Having served under Bill at Stiefel, I know firsthand how talented he is in the global commercialisation of products in today's healthcare environment and his experience is already providing an important impact to Clearside Biomedical," said Daniel White, Clearside's president and CEO.

"Bill brings a complementary vision to our company and a wealth of knowledge to the table that will help guide our company to achieving its goal of providing valuable medical solutions for patients suffering from sight-threatening illness."

4th April 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics